Data mining

Know whether the evidence can support your dataset before you fund it

Excelra goes beyond document retrieval to identify patents and papers with compound-level evidence that matches your scientific criteria. You get a grounded view of available structures, activity data, assay context, and likely yield for your target, modality, chemotype, or other defined scope.

Give medicinal chemistry and informatics teams a clear basis to proceed, refine the question, or stop before a low-yield build consumes budget and senior scientific time.

See if usable SAR exists
From search results to a fundable decision

Find the evidence, exclude the noise, and understand the yield

  • Search logic built around the scientific question Domain experts translate your scope into target synonyms, chemotype and modality constraints, endpoint families, inclusion and exclusion rules, and the right source mix. Paywalled and grey literature are included where access permits.
  • Scientific inclusion adjudication Each candidate is evaluated against agreed criteria. A positive source contains evidence worth extracting, such as an explicit structure–activity claim, an assay table, or a relevant compound series. Document count alone is not treated as evidence yield.
  • Patent-family-aware coverage Pharmaceutical patents can disclose large enumerated series, dense activity tables, and broader Markush context. Family-aware screening reduces duplicate counting across jurisdictions while preserving the disclosures most likely to contain usable SAR.
  • A decision your team can defend The output summarizes evidence density, productive source types, unresolved gaps, and the recommended route: proceed to schema-fit curation, evaluate an existing GOSTAR slice, refine the scope, or stop.
A practical feasibility deliverable

Evidence your team can evaluate, share, and act on

When to start here

Keep senior scientists focused while Excelra maps the evidence

Use this path to test training-set feasibility, define a competitive or patent landscape, support diligence, or determine whether an unfamiliar target or modality has enough public evidence to justify extraction.

PubMed and patent search tools retrieve documents. The additional work is scientific adjudication: deciding which disclosures meet the inclusion criteria, contain extractable SAR, and contribute distinct evidence. Mining produces that screened evidence base. Curation or a partial GOSTAR backfile becomes the next step when yield and schema fit support it.

Ask about your landscape

From evidence map to loadable rows

When the evidence base is sufficient, Excelra can continue into multi-tier-QC extraction of structures, targets, activities, units, and assay context, mapped to your chemical entity schema and linked back to source.

FAQ

Questions we hear from discovery leaders

Those tools are strong for retrieval. They do not apply your scientific inclusion criteria or produce a screened evidence inventory with source-level disposition. Excelra adds that adjudication so your team can estimate extractable SAR before funding full curation.

They can. The tradeoff is the time required to design searches, reconcile patent families, inspect dense disclosures, and document inclusion decisions. Excelra provides a dedicated scientific screening team while your internal experts retain control of the criteria.

If GOSTAR already shows strong coverage for your slice and its data model is acceptable, request a GOSTAR partial backfile coverage review instead. If you already have an approved source set and need schema-aligned rows, go directly to data curation.

Data mining

Find out if usable SAR exists

Share the scientific question, inclusion boundaries, and preferred source mix. That is enough to scope an initial feasibility assessment.

Protected by Cloudflare Turnstile. Do not enter confidential compounds or unpublished structures.